Hymenoptera venom allergens and associated immune effector pathways

Hymenoptera venom allergens and associated immune effector pathways constitute the molecular and cellular framework for insect sting hypersensitivity, a condition that can lead to life-threatening anaphylaxis [2, 3]. The system includes major allergens such as phospholipase A2 (Api m 1), hyaluronidase (Api m 2/Ves v 2), and Antigen 5 (Ves v 5), which act as the primary triggers for IgE-mediated Type I hypersensitivity [4, 10]. Upon exposure, these allergens cross-link IgE antibodies bound to the high-affinity FcεRI receptor on mast cells and basophils, initiating a signaling cascade that releases potent inflammatory mediators like histamine, leukotrienes, and tryptase [3, 8]. Therapeutic strategies primarily involve Venom Immunotherapy (VIT), which uses standardized venom extracts to induce peripheral immune tolerance [13, 15]. VIT works by shifting the immune response from a pro-inflammatory Th2 profile toward a regulatory T cell (Treg) and B cell (Breg) response, increasing the production of blocking IgG4 antibodies and IL-10 [3, 15]. Additionally, pharmacological agents such as epinephrine are used for acute management, while monoclonal antibodies like omalizumab may be employed to neutralize IgE in high-risk patients [2, 20].

Other names

Hymenoptera venom allergy (HVA) pathwaysInsect venom allergensVenom immunotherapy (VIT) targetsApid and vespid venom allergens

Allergen-specific immunotherapy (desensitization), IgE neutralization, adrenergic receptor activation, and H1 receptor antagonism.